赛杰 朱

1. Management of drug development projects from hit-to-lead phase (D2b) to selected proof-of-concept (sPoC) phase by extensive cross-functional collaboration with Chemistry, Biology, Pharmacology, DMPK, preclinical safety, pharmaceutical development unit, analytical development unit and chemical development unit. 2. Developability assessment and risk management of small molecular drug candidates by conducting physical form selection (salt, cocrystal and polymorph screening), and preclinical formulation development (solution, suspension, solid dispersion and microemulsion to support toxicological study). 3. Development of novel drug delivery systems (hydrogels, organogels, microparticles and insoluble salts) with unique features (e.g. sustained release and mucoadhesion) to meet the need of candidate screening in the early drug development stage and drug development. 4. Development of prototype conventional formulations as clinical formulation.

1. Management of drug development projects from hit-to-lead phase (D2b) to selected proof-of-concept (sPoC) phase by extensive cross-functional collaboration with Chemistry, Biology, Pharmacology, DMPK, preclinical safety, pharmaceutical development unit, analytical development unit and chemical development unit. 2. Developability assessment and risk management of small molecular drug candidates by conducting physical form selection (salt, cocrystal and polymorph screening), and preclinical formulation development (solution, suspension, solid dispersion and microemulsion to support toxicological study). 3. Development of novel drug delivery systems (hydrogels, organogels, microparticles and insoluble salts) with unique features (e.g. sustained release and mucoadhesion) to meet the need of candidate screening in the early drug development stage and drug development. 4. Development of prototype conventional formulations as clinical formulation.

1. Management of drug development projects from hit-to-lead phase (D2b) to selected proof-of-concept (sPoC) phase by extensive cross-functional collaboration with Chemistry, Biology, Pharmacology, DMPK, preclinical safety, pharmaceutical development unit, analytical development unit and chemical development unit. 2. Developability assessment and risk management of small molecular drug candidates by conducting physical form selection (salt, cocrystal and polymorph screening), and preclinical formulation development (solution, suspension, solid dispersion and microemulsion to support toxicological study). 3. Development of novel drug delivery systems (hydrogels, organogels, microparticles and insoluble salts) with unique features (e.g. sustained release and mucoadhesion) to meet the need of candidate screening in the early drug development stage and drug development.

1. Rational design, synthesis and evaluation of novel drug delivery systems (nanoparticles, micelles and polymeric conjugates) for cancer therapy based on the specific tumor microenvironment. 2. Cell culture and evaluation of cytotoxicity, cellular uptake and intracellular fate of the drug delivery systems. 3. Experimental tumor therapy including tumor model establishment, drug administration, evaluation of efficacy and immunohistology.

1. Design, synthesis and evaluation of a polymer-drug conjugate delivery system for improved cancer therapeutic efficacy and reduced side effects. (Doctoral thesis) 2. Evaluation of the inhibitory effect of a pharmaceutical excipient on P-glycoprotein and CYP enzymes, and the potential impact on oral absorption. 3. Development of an oral self-nanoemulsified drug delivery system for a poorly water soluble drug